| Dr Suellen Tucker Balestra, MD | |
|
243 Elm St, Claremont, NH 03743-4921 | |
| (603) 542-7771 | |
| Not Available |
| Full Name | Dr Suellen Tucker Balestra |
|---|---|
| Gender | Female |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 243 Elm St, Claremont, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295874493 | NPI | - | NPPES |
| 40200340 | Medicaid | NH | |
| 0000932 | Other | VT | MEDICAID VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 6628 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suellen Tucker Balestra, MD 14 Sevens Rd, Lebanon, NH 03766 Ph: (603) 448-6140 | Dr Suellen Tucker Balestra, MD 243 Elm St, Claremont, NH 03743-4921 Ph: (603) 542-7771 |
News Archive
Physicians at Monash University and The Alfred Hospital in Melbourne, Australia describe the logistic, medical, and societal challenges faced in treating spine trauma in morbidly obese patients.
In the interest of advancing patient safety and improving care, the North Shore-LIJ Health System today announced with GE Healthcare the $12 million purchase of 15 GE Low-Dose CT Scanners that will be installed at 10 locations throughout the New York area over the next year.
Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.
Safety new medical providers can substantially increase their telemedicine services with modest investments in new staff and technology, a move that can help them expand patients' access to specialized medical care, according to a new RAND Corporation study.
The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington's disease (HD) using structural and chemical biology In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.
› Verified 1 days ago
Dr. Bruce Jay Lewis, M.D Pathology Medicare: Not Enrolled in Medicare Practice Location: 243 Elm St, Claremont, NH 03743 Phone: 603-542-7771 |